In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diagnostic microbiology and infectious disease

• Publication date

  2011-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.diagmicrobio.2010.10.032PMID 21353964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ceftaroline

  2012cited by this paper
• Introduction to the CANWARD Study (2007-2009).

  2011cited by this paper
• Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.

  2011cited by this paper
• Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

  2011cited by this paper
• Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

  2010cited by this paper
• Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008)

  2010cited by this paper
• Ceftobiprole: Farewell or just a delay?

  2010cited by this paper
• Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies.

  2009cited by this paper
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

  2009cited by this paper
• Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections

  2009cited by this paper
• A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.

  2008cited by this paper
• Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.

  2008cited by this paper
• Ceftobiprole

  2008cited by this paper
• Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).

  2008cited by this paper
• Ceftobiprole (BPR) versus Ceftazidime (CAZ) Combined with Linezolid (LZD) for Treatment of Patients with Nosocomial Pneumonia (NP)

  2008cited by this paper
• Pneumonia caused by methicillin-resistant Staphylococcus aureus.

  2008cited by this paper
• Epidemiology of methicillin-resistant Staphylococcus aureus.

  2008cited by this paper
• In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models

  2008cited by this paper
• Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006).

  2008cited by this paper
• Interactions of Ceftobiprole with β-Lactamases from Molecular Classes A to D

  2007cited by this paper
• Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus

  2007cited by this paper
• Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.

  2007cited by this paper
• Outcome of Vancomycin Treatment in Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia

  2007cited by this paper
• Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects

  2007cited by this paper
• Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae

  2007cited by this paper
• Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

  2007cited by this paper
• Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.

  2007cited by this paper
• Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria

  2007cited by this paper
• Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin

  2005cited by this paper
• Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin

  2005cited by this paper
• Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.

  2004cited by this paper
• In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

  2002cited by this paper
• Multiplex PCR Strategy for Rapid Identification of Structural Types and Variants of the mec Element in Methicillin-Resistant Staphylococcus aureus

  2002cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper

• Antimicrobial Resistance Profile of Different Clinical Isolates against Augmentin, Imipenem and Ceftriaxone

  2023cites this paper
• New Antibiotics for Staphylococcus aureus Infection: An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)

  2023cites this paper
• Ceftobiprole medocaril for the treatment of pneumonia

  2023influential citation
• Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.

  2022cites this paper
• Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management

  2021cites this paper
• Antimicrobial Resistance Profile of Different Clinical Isolates against Rocephin

  2021cites this paper
• Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Bio-Medicine

  2020cites this paper
• New cephalosporins for the treatment of pneumonia in internal medicine wards

  2020cites this paper
• Overcoming Antibiotic Resistance: New Perspectives

  2020cites this paper
• Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

  2020cites this paper
• Light and Shade of Antibiotics Recently Approved and in Advanced Development for Critically Ill Patients

  2019cites this paper
• Emerging drugs for treating methicillin-resistant Staphylococcus aureus

  2019cites this paper
• Ceftobiprole: drug evaluation and place in therapy

  2019cites this paper
• In vitro evidence of the synergistic interaction of ceftopibrole and other antibiotics against multidrug-resistant Gram-negative isolates.

  2019cites this paper
• Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

  2019cites this paper
• Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

  2018cites this paper
• Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

  2018cites this paper
• Infections Caused by Antimicrobial Drug-Resistant Saprophytic Gram-Negative Bacteria in the Environment

  2017cites this paper
• Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA

  2017cites this paper
• Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole

  2016cites this paper
• Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections

  2016cites this paper
• Safety profiles of old and new antimicrobials for the treatment of MRSA infections

  2016cites this paper
• New therapeutic options for respiratory tract infections

  2016cites this paper
• New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections

  2015cites this paper
• Development of novel antibacterial drugs to combat multiple resistant organisms

  2015cites this paper
• Modern Therapeutic Approaches Against Pseudomonas aeruginosa Infections.

  2015cites this paper
• Elucidating the genetic basis for catheter blockage and encrustation in Proteus mirabilis

  2014cites this paper
• Coagulase-Negative Staphylococci

  2014cites this paper
• New antibiotics for bad bugs: where are we?

  2013cites this paper
• Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia

  2013influential citation
• Emergence and management of drug-resistant enterococcal infections

  2013cites this paper
• Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on

  2013cites this paper
• The Utility of Admission Screening for the Prevention of Nosocomial Transmission of Extended-spectrum β-Lactamase Producing Enterobacteriaceae

  2012cites this paper
• Decreased Susceptibility to Noncarbapenem Antimicrobials in Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Toronto, Canada

  2012cites this paper
• Introduction to the CANWARD Study (2007-2009).

  2011cites this paper
• Treatment Options for Gram-Positive and Gram-Negative Bacteria: Focus on Ceftriaxone

  2011cites this paper